AstraZeneca Results Presentation Deck
AstraZeneca in Lung Cancer
Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030
Est. epi (G7)
10 sensitive
c.70%
EGFRm
c.16%
Other tumor
drivers c.12%
HER2
c.2%
resectable
Stg. I-III
~200K
Imfinzi
AEGEAN
volrustomig + CTX
NEOCOAST-2
Tagrisso
ADAURA
Tagrisso
neo-ADAURA
established SoC
unresectable
Stg. 1-11
~30K
Imfinzi
w/ SBRT
PACIFIC-4
Stg. III
~70K
CRT → Imfinzi
PACIFIC
CRT + Imfinzi
PACIFIC-2
Imfinzi combos
PACIFIC-8, -9
improvements across
PD-L1 spectrum
CRT → Tagrisso
LAURA
CRT → Imfinzi
PACIFIC
1L
~350K
Imfinzi + Imjudo + CTx
POSEIDON
Dato-DXd + 10
rilvegostomig
(PD1/TIGIT)
ARTEMIDE-1
TROPION-Lung08
AVANZAR
TROPION-Lung07 TROPION-Lung04/02
Enhertu + 10
DESTINY-Lung03
Tagrisso
FLAURA
Tagrisso + CTx
FLAURA2
metastatic
Enhertu
DESTINY-Lung04
volrustomig
(PD1/CTLA4)
2L+
~290K
Imfinzi + ceralasertib
LATIFY
Dato-DXd
TROPION-Lung01
AZD9592 (EGFR/CMET ADC)
EGRET
sabestomig
(PD1/TIM3)
savolitinib + Tagrisso
SAFFRON/SAVANNAH
AZD9592 (EGFR/CMET ADC)
EGRET
Dato-DXd
TROPION-Lung01
TROPION-Lung05
Enhertu
DESTINY-Lung02
APPENDIX | Oncology tumour maps
●
Leading the future of
lung cancer treatment
Tagrisso established TKI
backbone in EGFRm
Imfinzi leading 10 in unresectable
Advancing best-in-class ADCs to
replace systemic chemotherapy
Delivering next-wave bispecifics
to improve on PD1/PD-L1
Developing novel combinations,
including 10 + ADC
Investing behind new
technologies and platforms,
including cell therapy,
testing/screening
Est epi (G7) = estimated epidemiology across G7 (US, EU5, JP); Stg. = stage; CTx = chemotherapy; SBRT = stereotactic body radiation therapy; CRT = chemoradiotherapy; pembro = pembrolizumab; 10 = immunotherapy; ADC = antibody-drug conjugate; PD1 =
programmed cell death protein 1; EGFR = epidermal growth factor receptor; c-MET = mesenchymal-epithelial transition factor; TIGIT = T-cell immunoreceptor with immunoglobulin and ITIM domains; CTLA4 = cytotoxic T-lymphocyte associated protein 4;
35 TIM3 = T-cell immunoglobulin and mucin domain-containing protein 3; SoC = standard of care; TKI = tyrosine kinase inhibitor.
B
Collaboration partners: Daiichi Sankyo (Enhertu, Dato-DXd), Compugen (rilvegostomig).View entire presentation